Jonathan Poole

Senior Vice President, Finance · Vertex Pharmaceuticals

Biopharmaceuticals

Jonathan Poole is senior vice president of finance at Vertex Pharmaceuticals. His career combines investment banking and private equity with finance leadership at Shire, Genocea Biosciences and Evelo Biosciences.

Last reviewed: Nov 2, 2026

Jonathan Poole

Senior Vice President, Finance
Vertex Pharmaceuticals

Last Reviewed: November 2, 2026

Executive Summary

Jonathan Poole is senior vice president of finance at Vertex Pharmaceuticals. His career combines investment banking and private equity with finance leadership at Shire, Genocea Biosciences and Evelo Biosciences.

Career Highlights

  • Joined Vertex as senior vice president of finance in March 2020.
  • Previously served as CFO of Genocea Biosciences and Evelo Biosciences.
  • Named Vertex’s next CFO, with the appointment scheduled to take effect January 1, 2027.

Professional Journey

Poole began his career in the United Kingdom, working in investment banking at UBS Warburg and ING Barings. He also worked as an investment manager at Avanti Capital, a private equity firm.

He joined Shire in December 2006 and progressed through finance and strategic-planning positions. From May 2010 to June 2013, he was divisional CFO of Shire Human Genetic Therapies, the company’s rare-disease business. He subsequently became senior vice president of finance for pipeline and technical operations, supporting global business development, research and development, and technical operations.

Poole moved to Genocea Biosciences as CFO in April 2014. He remained there until March 2018, when he joined Evelo Biosciences as CFO, also serving as treasurer. He held that position until March 2020.

At Vertex, Poole leads finance support for corporate, commercial, research and development, manufacturing and other functions. His work includes supporting acquisitions and their integration. In August 2026, Vertex selected him to become executive vice president and CFO effective January 1, 2027; until that transition, he remains senior vice president of finance.

Poole joined Acadia Pharmaceuticals’ board and audit committee in March 2026. Earlier, he served on Codiak Biosciences’ board and chaired its audit committee from 2018 to 2020.

Education

Poole holds a Bachelor of Science in biological sciences from Durham University and an MBA from London Business School.